Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.
Fiche publication
Date publication
avril 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUENOT Dominique
Tous les auteurs :
Goïta AA, Guenot D
Lien Pubmed
Résumé
Colorectal cancer is one of the most common cancers, and diagnosis at late metastatic stages is the main cause of death related to this cancer. This progression to metastasis is complex and involves different molecules such as the chemokine CXCL12 and its two receptors CXCR4 and CXCR7. The high expression of receptors in CRC is often associated with a poor prognosis and aggressiveness of the tumor. The interaction of CXCL12 and its receptors activates signaling pathways that induce chemotaxis, proliferation, migration, and cell invasion. To this end, receptor inhibitors were developed, and their use in preclinical and clinical studies is ongoing. This review provides an overview of studies involving CXCR4 and CXCR7 in CRC with an update on their targeting in anti-cancer therapies.
Mots clés
ACKR3, chemokine, colorectal cancer, epigenetics, metastasis, microenvironment, prognosis, resistance, signaling pathways, therapy
Référence
Cancers (Basel). 2022 Apr 2;14(7):